Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great time to buy, just picked up some more, 52 week low, i cant see it going lower then it is
Bought more at $1.50
AVI BioPharma and Naval Medical Research Center Successfully Complete Simultaneous Rapid-Response Exercises Against Bacterial an
Date : 06/16/2011 @ 8:00AM
Source : MarketWire
Stock : AVI BioPharma, Inc. (AVII)
Quote : 1.39 0.03 (2.21%) @ 7:26AM
AVI BioPharma and Naval Medical Research Center Successfully Complete Simultaneous Rapid-Response Exercises Against Bacterial an
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Thursday 16 June 2011
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, and the Naval Medical Research Center (NMRC) in Silver Spring, MD, today announced the successful completion of a formal rapid-response exercise conducted by the Joint Project Manager Transformational Medical Technologies (JPM-TMT) of the Defense Threat Reduction Agency (DTRA). The exercise involved two undisclosed bacterial and viral threats and exhibited AVI's continued success in the development of a credible rapid response capability utilizing its RNA-based therapeutic technologies against pathogenic threats. Previously, AVI successfully completed its first formal rapid-response exercise against the pandemic H1N1 influenza virus (swine flu) in 2009 and one against the dengue virus in 2010.
The key outcome of this newest rapid response exercise was AVI's simultaneous conception, design and manufacture in 18 days of two novel RNA-based drug candidates, one against a gram negative bacterial target and the second against a viral target. The drug candidates use AVI's proprietary phosphorodiamidate morpholino oligomer (PMO) technologies, including PMOplus™, a positively charged version of its intrinsically charge-neutral PMO chemistry. This exercise is part of JPM-TMT 's and AVI's ongoing research efforts to develop and refine an efficient rapid-response capacity that includes the capability of responding to a real-world emerging infectious disease or biological threat by rapidly identifying the threat, designing and producing therapeutic candidates against the threat, and then evaluating the preclinical efficacy of therapeutic candidates.
"By addressing two pathogenic threats simultaneously, including for the first time a bacterial threat, this exercise further tested AVI's demonstrated ability to rapidly design therapeutics against emerging viral and bacterial threats using our PMO-based platform chemistries, and builds on our other successful rapid response exercises," commented Chris Garabedian, AVI's CEO and president. "We look forward to supporting JPM-TMT and DTRA to refine the rapid-response capability and also to potentially broaden our collaborative efforts with NMRC through future contracts or a Cooperative Research and Development Agreement (CRADA) for the development of RNA-based therapeutics for the treatment of infectious diseases, including both viral and bacterial threats."
About the Defense Threat Reduction Agency
The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense (DoD) that address the threat by weapons of mass destruction (WMD). DTRA's mission is to safeguard the United States and its allies from chemical, biological, radiological, nuclear, and high-yield explosive WMDs by providing capabilities to reduce, eliminate, and counter the threat and mitigate its effects. DTRA combines DoD resources, expertise, and capabilities to ensure the United States remains ready and able to address present and future WMD threats. For more information on DTRA, visit www.dtra.mil.
About Transformational Medical Technologies
Transformational Medical Technologies (TMT) was created by the DoD to protect the Warfighter from emerging and genetically engineered biological threats by discovering and developing a wide range of medical countermeasures through enhanced medical research, development, and test and evaluation programs. The TMT Program office is matrixed from the Joint Science and Technology Office - DTRA and Joint Program Executive Office - Chemical and Biological Defense with oversight from the Office of the Secretary of Defense. For more information on TMT, visit www.tmti-cbdefense.org.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging a highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy, and multiple drug candidates that are in clinical development for the treatment of infectious diseases. For more information, visit www.avibio.com.
Forward-Looking Statements and Information
This press release contains statements that are forward-looking, including statements about AVI's partnerships with JPM-TMT, DTRA and NMRC, AVI's PMO-based platform chemistries and their ability to protect against emerging viral and bacterial threats, and the efficacy, potency and utility of AVI's product candidates in the treatment of rare and infectious diseases. These forward-looking statements involve risks and uncertainties, many of which are beyond AVI's control. Known risk factors include, among others: clinical trials may not demonstrate safety and efficacy of any of AVI's drug candidates; any of AVI's drug candidates may fail in development, may not receive required regulatory approvals, or be delayed to a point where they do not become commercially viable; and the U.S. government could fail to fund, or terminate, any of AVI's government programs. Any of the foregoing risks could materially and adversely affect AVI's business, results of operations and the trading price of its common stock. For a detailed description of risks and uncertainties AVI faces, you are encouraged to review the official corporate documents filed with filed with the Securities and Exchange Commission. AVI does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings.
AVI Media and Investor Contact:
David A. Walsey
Senior Director, Investor Relations & Corporate Communications
425.354.5140
Email Contact
I dont understand why it was down so much today.... thought if anything it would be up, I been looking for something else and cant find anything
AVI BioPharma Provides Update on Initiation of Eteplirsen Phase 2 Clinical Trial
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Thursday 9 June 2011
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today provided an update on the initiation of its Phase 2 clinical trial of eteplirsen, the Company's lead therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD).
On June 8th, following a meeting of the Institutional Review Board (IRB) of Nationwide Children's Hospital in Columbus, Ohio, the site of the Phase 2 clinical trial, AVI received an IRB request to modify the clinical trial protocol. AVI is reviewing the request, which is not related to the safety or expected activity of eteplirsen, and anticipates submitting a revised Phase 2 clinical trial protocol to the IRB later this month. The U.S. Food and Drug Administration (FDA) has not communicated any concerns regarding the original design of the Phase 2 clinical trial at this time and the Company intends to provide any updates on this protocol to the FDA.
"We will work quickly and deliberately to address the IRB's request, and we expect to initiate the Phase 2 trial in the third quarter," said Chris Garabedian, AVI's President and CEO. "Furthermore, we are confident that we will remain on track in initiating a pivotal trial in the second half of 2012. We remain fully committed to eteplirsen development and its potential as an important treatment for DMD."
Based on the expected initiation of the Phase 2 trial in the third quarter, AVI anticipates study results in the second quarter of 2012.
About Institutional Review Boards
Institutions conducting clinical trials must submit each trial protocol to an independent institutional review board for review and approval prior to trial initiation. Generally, the institutional review boards will consider, among other things, clinical trial design, participant informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. While institutional review boards are mandated and overseen by the U.S. Department of Health and Human Services and FDA, they are not affiliated with either of these governmental entities.
About Eteplirsen
Eteplirsen is AVI's lead systemically administered drug candidate for the treatment of a substantial subgroup of patients with Duchenne muscular dystrophy (DMD). Data from clinical studies of eteplirsen in DMD patients have demonstrated a broadly favorable safety and tolerability profile and restoration of dystrophin protein expression. AVI plans to initiate a Phase 2 study of eteplirsen in the third quarter of 2011 and is currently conducting NDA-enabling activities to support the initiation of a pivotal Phase 3 study in the second half of 2012.
Grubb & Ellis Healthcare REIT II Extends Initial Public Offering
Grubb & Ellis (NYSE:GBE)
Intraday Stock Chart
Today : Tuesday 7 June 2011
Grubb & Ellis Healthcare REIT II, Inc. today announced that its board of directors has elected to extend the company's initial public offering of shares of its common stock, in accordance with terms established in its prospectus. The company's initial public offering, which was scheduled to terminate on Aug. 24, 2011, will now continue through Aug. 24, 2012. The company also announced today that it has renewed its advisory agreement and dealer manager agreement with subsidiaries of its sponsor, Grubb & Ellis Company.
As of May 31, 2011, Grubb & Ellis Healthcare REIT II has sold approximately 26.3 million shares of its common stock, excluding the shares issued under its distribution reinvestment plan, for approximately $262,806,000 through its initial public offering, which began at the end of the third quarter of 2009.
To date, the company has made 21 geographically diverse acquisitions comprised of 48 buildings valued at approximately $336 million, based on purchase price in the aggregate.
AVI BioPharma Names Ed Kaye, M.D., Chief Medical Officer
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Monday 6 June 2011
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today the appointment of Ed Kaye, M.D., as Chief Medical Officer effective June 20, 2011. The addition of Dr. Kaye, a recognized industry leader in the development of therapeutics for the treatment of rare genetic diseases, and an expert in pediatric neurological diseases, continues AVI's strategy in assembling an executive team with industry-leading experience.
Dr. Kaye, 62, joins AVI from Genzyme where he served as Group Vice President for Clinical Development and Therapeutic Head for Lysosomal Storage Disorders and Neurodegenerative Diseases since 2007. He held Vice President-level leadership roles at Genzyme in Clinical Development and Medical Affairs over the last 10 years, helping build an industry-leading company in rare genetic diseases. Dr. Kaye also has specific experience with pediatric neuromuscular conditions. He played a leadership role in gaining Myozyme's approval for Pompe Disease and he oversaw all of Genzyme's collaborations in this field, including the development of ataluren for Duchenne Muscular Dystrophy (DMD).
"Ed brings to AVI significant knowledge and experience in getting drugs approved in rare diseases, an expertise in pediatric neurology built over decades, and strong existing relationships with the muscular dystrophy community," said Chris Garabedian, AVI's CEO and President. "Ed's experience in building Genzyme's success in rare genetic diseases is a perfect fit as we look to apply our RNA-based technology to other rare disease indications, including efforts to accelerate other exon-skipping drugs for DMD beyond eteplirsen."
Dr. Kaye commented, "I believe eteplirsen holds unique potential to have a major impact on the treatment of Duchenne Muscular Dystrophy. The data on eteplirsen in DMD patients who would benefit from AVI's lead exon-skipping drug is very encouraging and I look forward to moving the program into a pivotal trial and toward regulatory approval. I'm excited to be a part of AVI's new executive team and applying my experience in building a successful biopharmaceutical company focused on genetic-based drug development."
Dr. Kaye will replace AVI's current Chief Medical Officer, Dr. Stephen Shrewsbury, who will remain with the Company until August 1, 2011 to help with the transition. Dr. Kaye will have an office at AVI's headquarters in Bothell, WA, but will also establish a rare disease development operation for AVI in Cambridge, MA, an important hub for industry and academia in the area of rare genetic diseases.
Before joining Genzyme in 2001 as Vice President of Clinical Research, Dr. Kaye was Chief of Biochemical Genetics at Children's Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at University of Pennsylvania School of Medicine. Before this, he was Chief of Pediatric Neurology and Director of the Barnett Mitochondrial Laboratory at St. Christopher's Hospital for Children in Philadelphia. Earlier experience includes Section Head of neurometabolism, Pediatric Neurology, at The Floating Hospital for Children at Tufts University and Research Fellow in gene therapy at Massachusetts General Hospital.
Dr. Kaye is a member of several scientific advisory boards, including the CureDuchenne, CureCMD (Congenital Muscular Dystrophy) and Spinal Muscular Atrophy Foundation advisory boards. He is also a Neurological Consultant at Children's Hospital of Boston and is on the editorial boards of a number of journals, including Journal of Child Neurology and Pediatric Neurology and previously served on the board of Annals of Neurology. Dr. Kaye received his medical education and pediatric training at Loyola University Stritch School of Medicine and University Hospital, child neurology training at Boston City Hospital, Boston University, and completed his training as a neurochemical research fellow at Bedford VA Hospital, Boston University.
good buy popper, i had a bid in for .028, great buy at those levels. but i guess i was a little late, you got it, good buy
something is a brewing today
awesome start, 1.5 mill in the first hour
Grubb & Ellis Healthcare REIT II Acquires Five Medical Office Buildings in New Jersey and Arkansas
Grubb & Ellis (NYSE:GBE)
Intraday Stock Chart
Today : Thursday 2 June 2011
Grubb & Ellis Healthcare REIT II, Inc. today announced that it has acquired four properties comprised of five medical office buildings; four of the buildings are located in Arkansas, the fifth in New Jersey. The $44 million purchase closed on May 26, 2011.
Totaling approximately 179,000 square feet, each of the medical office buildings are located on the campus of, or fully leased to, a leading regional medical center.
"This five building transaction is the first of a two phase acquisition of a portfolio of eight medical office buildings," said Danny Prosky, president and chief operating officer. "Once we have concluded the second phase, Grubb & Ellis Healthcare REIT II's portfolio of clinical medical buildings will have expanded to include regional portfolios in Greater New York and central Arkansas, and we will have acquired our first property in the state of Washington."
The individual properties included in the transaction are:
Jersey City Medical Office Building - Jersey City, N.J.
Built in 2010, Jersey City Medical Office Building is a five-story, 100 percent leased, 68,000-square-foot Class A facility on the campus of Jersey City Medical Center, a 332-bed community hospital with full inpatient and outpatient services. The medical center lies just across the Hudson River from Manhattan and leases 50 percent of the medical office building, which has no significant lease rollover until 2020.
Medical Park Place I & II - Benton, Ark.
Medical Park Place I & II is a four-story, two-tower medical office complex totaling approximately 79,000 square feet on the campus of Saline Memorial Hospital in Benton, an affluent suburb of Little Rock. Built in 1992 and 1999, the medical office buildings are connected to each other and the hospital via sky bridges. Saline Memorial Hospital is a full-service, 167-bed acute care facility that has served the region for more than 50 years.
Home Health Medical Complex – Benton, Ark.
Home Health Medical Complex, a two-story medical office building totaling approximately 10,000 square feet, also located on the campus of Saline Memorial Hospital, which also leases the entire building under a triple net lease agreement that expires in 2024.
Bryant Medical Office Building – Bryant, Ark.
Built in 1993 and fully renovated in 2006, Bryant Medical Office Building is a high-quality, single-story medical office building comprised of approximately 22,000 square feet of rentable space at 23157 Interstate 30 in Bryant.. The building is located roughly 10 miles southwest of downtown Little Rock and nine miles northeast of Saline Memorial Hospital, which leases 86 percent of the facility via two leases that expire in 2024 and 2025.
The five medical office buildings were acquired from an unaffiliated third party represented by Jeffrey H. Cooper and Philip B. Mahler of Savills, LLC. Grubb & Ellis Healthcare REIT II financed the acquisition using cash proceeds from its offering, $31.1 million in borrowings under its line of credit with Bank of America, N.A., and $5 million in borrowings from Keybank, N.A.
As of May 20, 2011, Grubb & Ellis Healthcare REIT II has sold approximately 25,608,950 shares of its common stock, excluding the shares issued under it distribution reinvestment plan, for approximately $255,509,000 through its initial public offering, which began at the end of the third quarter of 2009.
To date, the REIT has made 21 geographically diverse acquisitions comprised of 48 buildings valued at approximately $336 million, based on purchase price in the aggregate.
should be a good day
Its awesome
I dont understand all day the Ask has been lower then the last sale, why is that
Alphatec Spine to Present at the Jefferies 2011 Global Healthcare Conference
Alphatec Holdings, Inc. (MM) (NASDAQ:ATEC)
Intraday Stock Chart
Today : Wednesday 1 June 2011
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, today announced it will present at the Jefferies 2011 Healthcare Conference in New York, New York on Wednesday, June 8, 2011 at 1:00 pm Eastern Time.
During such presentation, Dirk Kuyper, Alphatec Spine's President and CEO, will provide an overview of the Company's activities. A live audio webcast of the presentation at the Jefferies 2011 Healthcare Conference will be accessible through the Company's investor relations website at www.alphatecspine.com. An archived edition of the presentation will be available later that day and will be available for at least 30 days afterwards.
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative, surgeon-driven design that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis, stenosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its subsidiary, Scient'x S.A.S., via a direct salesforce in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa, South America and Latin America. In Asia and Australia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc., and through Scient'x's distributors in China, Korea and Australia.
The Alphatec Holdings, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3520
CONTACT: Michael O'Neill
Chief Financial Officer
Alphatec Spine, Inc.
(760) 494-6746
investorrelations@alphatecspine.com
Westwicke Partners
Lynn C. Pieper
(415) 202-5678
lynn.pieper@westwicke.com
Grubb & Ellis Provides Update on Strategic Process
Grubb & Ellis (NYSE:GBE)
Intraday Stock Chart
Today : Tuesday 31 May 2011
Grubb & Ellis Company (NYSE: GBE), a leading real estate services and investment firm, today issued the following update regarding the strategic process currently being conducted.
As previously disclosed, the Board of Directors of Grubb & Ellis initiated a process in the first quarter of 2011 to explore strategic alternatives for the company, with the goals of maximizing value for all stakeholders and strengthening the company's competitive position. This process included hiring JMP Securities to explore the potential sale or merger of the company and engaging FBR Securities to market for sale the company's wholly owned but separately managed subsidiary, Daymark Realty Advisors.
The company received initial indications of interest from numerous strategic and financial buyers after hiring JMP Securities on March 21, and on March 30 it announced the signing of a loan agreement with Colony Capital LLC, which included a 60-day exclusivity period for Colony to explore a larger strategic transaction. As of May 29, Colony's exclusivity period ended, which allows Grubb & Ellis to actively engage in discussions with additional parties, while continuing discussions with Colony.
In addition, the company has made significant progress in the Daymark process and expects to complete a transaction with respect to Daymark. Daymark is a full service property and asset management company and is responsible for the management of the company's tenant-in-common portfolio, which consists of 30 million square feet of commercial real estate, including 8,700 apartment units and nearly 5,000 investors.
"We have already made significant progress with both initiatives and now that we have expanded the pool of potential strategic partners the Board and management are intent on bringing the strategic process to conclusion in a manner that creates value for all of our stakeholders," said Thomas P. D'Arcy, president and chief executive officer of Grubb & Ellis. "The market reaction to our core real estate services and non-traded REIT business – with its broad platform, talented professionals and deep client and investor base – has been very strong. At the same time, Daymark has attracted strong interest from a range of potential buyers."
There can be no assurances that the company will reach an agreement for the sale of Daymark or successfully conclude negotiations with a strategic investor. The company will continue to provide updates on both initiatives as appropriate.
About Grubb & Ellis Company
Grubb & Ellis Company (NYSE: GBE) is one of the largest and most respected commercial real estate services and investment companies in the world. Our 5,200 professionals in more than 100 company-owned and affiliate offices draw from a unique platform of real estate services, practice groups and investment products to deliver comprehensive, integrated solutions to real estate owners, tenants and investors. The firm's transaction, management, consulting and investment services are supported by highly regarded proprietary market research and extensive local expertise. Through its investment management business, the company is a leading sponsor of real estate investment programs. For more information, visit www.grubb-ellis.com.
Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the company's actual results and events in future periods to be materially different from those anticipated, including risks and uncertainties related to the financial markets. Such factors which could adversely affect the company's ability to obtain these results include, among other things: (i) a continued or further weakness in the company's Investment Management and/or Transaction Services businesses, including the velocity and volume of equity raised with respect to the Investment Management business and insufficient margins with respect to its Transaction Services business; (ii) the general economic pressures on transaction values of sales and leasing transactions and businesses in general; (iii) a continued weakness in real estate markets and values; (iv) the unavailability of credit to finance real estate transactions in general and the company's tenant-in-common programs, in particular; (v) the success of current and new investment programs; (vi) the success of new initiatives and investments; (vii) the inability to attain expected levels of revenue, performance, brand equity in general, and in the current macroeconomic and credit environment, in particular; (viii) the inability of the company's subsidiary, NNN Realty Advisors, Inc. to come into compliance with the contractually specified net worth requirements with respect to approximately 30 percent of the tenant-in-common programs managed by the company; (ix) the nature and amount of the net intercompany balance between the company and its wholly-owned subsidiary, Daymark Realty Advisors, Inc., (x) the occurrence of bankruptcies by unaffiliated, individual investor entities in the company's tenant-in-common programs which may result in demands for payments on certain non-recourse/carve-out guaranty and indemnification obligations issued by the company's subsidiaries, which may, in turn, in the event such guaranty or indemnification obligations cannot be met, result in a cross-default under the company's issued and outstanding Convertible Senior Notes; (xi) the ultimate outcome in various legal proceedings concerning tenant-in-common programs sponsored by the company's subsidiaries, including the arbitration proceeding with respect to the Met 10 Center in Texas; and (xii) other factors described in the company's annual report on Form 10-K for the fiscal year ending December 31, 2010 and Form 10-Q for the quarter ended March 31, 2011, and in other Current Reports on Form 8-K filed by the company from time to time with the Securities and Exchange Commission. The company does not undertake any obligation to update forward-looking statements.
SOURCE Grubb & Ellis Company
Please tell us which other boards. thanks
i believe no shares traded since 12 noon, might be something in the works, hold on tight
VIGS seems like a shell thats going to happen very very soon, worth checking out
good post, very interesting
thats great lmao
got to love the MMs, 180,000 shares today and if you click on trades, its listing 34 trades and there all buys, lol, can someone explain that to me
wow , one little tiny post and look what got started, geeeze,
Just maken sure everone is still here and that no one got lost :) got to quiet, had to check
Just maken sure everone is still here and that no one got lost :) got to quiet, had to check
Bama, I can Hear a pin drop here, so quiet,
Point Blank Solutions 5/18/11
Today's hearing was not only a status hearing on the bankruptcy proceedings, but also a hearing on the adversarial proceedings brought against PBSOQ in April, 2011 by the brother of the former CEO.
'Two witnesses were examained and cross examined today. Jim Henderson, CEO and Chairman of the Board of Point Blank Solutions was first up as witness. The line of questioning for both witnesses was essentially the same; how much time would be spent on the adversary proceeding vs running the business. Mr. Henderson is cool under pressure and admitted to being fairly well paid to be so (including benefits, in excess of $1 million dollars). He testified to the amount of time spent not only working on the restructuring of the company, both operationally as well as financially, but also the time spent reassuring customers and clients of the company who have been concerned since the company declared bankruptcy.
Scott Avila, Chief Restructuring Officer of Point Blank Solutions was the second witness to be heard today, and he also testified to the amount of time that Henderson spends running the company and working on the restructuring. Avila is responsible for the financial restructuring guidance, but reports to both Henderson and the Board of Directors.
Ultimately, Judge Walsh ordered a 90 day stay on the adversary proceeding, during which time the BK proceedings will continue, possibly bringing Point Blank close to a confirmation process at the end of the 90 days. Judge Walsh will hear arguments to extend the 90 day stay at the end of the 90 days, and will rule depending on the progress of the BK.
Grubb & Ellis Healthcare REIT II Acquires 10 Medical Office Buildings in Arkansas, Louisiana, New Mexico and Texas
Grubb & Ellis (NYSE:GBE)
Intraday Stock Chart
Today : Thursday 19 May 2011
Grubb & Ellis Healthcare REIT II, Inc. today announced that it has acquired the Dixie-Lobo Medical Office Building Portfolio of eight properties consisting of 10 medical office buildings located in Arkansas, Louisiana, New Mexico and Texas.
Totaling more than 156,000 square feet, the Dixie-Lobo Medical Office Building Portfolio includes facilities that range in size from 10,000 to 33,000 square feet with an average size of 16,000 square feet. Each of the 10 medical office buildings are located on the campus of local hospitals that are their sole tenant, six of which are affiliated with Community Health Systems, one of the nation's largest operators of general acute care hospitals in non-urban and mid-size markets. The remaining four buildings are located on the campuses of, and leased to, hospitals affiliated with Christus Spohn Health System and Signature Hospital Corporation. The facilities are master leased to the hospitals with expirations staggered between November 2015 and August 2017. Each of the hospital-tenants have four five-year renewal options.
"The Dixie-Lobo Medical Office Building Portfolio epitomizes what Grubb & Ellis Healthcare REIT II values in medical office acquisitions," said Danny Prosky, president and chief operating officer. "They are all located on thriving hospital campuses with long-term stabilized tenancy, are immediately accretive to our bottom line and supportive of our investor distribution. We are very pleased to add these properties to our high quality portfolio of clinical medical buildings."
The 10 buildings that comprise the Dixie-Lobo Medical Office Building Portfolio are:
302 Bill Clinton Drive, Hope, Ark. A single-story, 9,000-square-foot property on the campus of Medical Park Hospital.
1920 W. Sale Road, Lake Charles, La. A single-story, 15,000-square-foot building on the campus of Women & Children's Hospital.
2420 W. Pierce St., Carlsbad, N.M. A two-story, 24,000-square-foot building on the campus of Carlsbad Medical Center.
5419 N. Lovington Highway, Hobbs, N.M. A single-story, 15,000-square-foot building on the campus of Lea Regional Medical Center.
2510 & 2420 E. Main St., Alice, Texas. Two single-story buildings totaling 25,000 square feet on the campus of Christus Spohn Hospital Alice.
302 Medical Park Drive, Lufkin, Texas. A single-story, 15,000-square-foot building on the campus of Woodland Heights Medical Center.
110 Medical Drive, Victoria, Texas. A single-story, 33,000-square-foot building on the campus of De Tar Hospital North.
2112 Regional Medical Drive, Wharton, Texas. Two single-story buildings totaling 20,000 square feet on the campus of Gulf Coast Medical Center.
Dixie-Lobo Medical Office Building Portfolio was acquired from eight individual selling entities that are all directly or indirectly controlled by Seavest, Inc. or an affiliate of Seavest, an unaffiliated third party. The transaction was a private, off-market deal. Grubb & Ellis Healthcare REIT II financed the acquisition with a $23.24 million loan assumption and cash proceeds received from its offering.
As of May 6, 2011, Grubb & Ellis Healthcare REIT II has sold approximately 24,372,675 shares of its common stock, excluding the shares issued under it distribution reinvestment plan, for approximately $243,165,000 through its initial public offering, which began at the end of the third quarter of 2009.
To date, the REIT has made 20 geographically diverse acquisitions comprised of 43 buildings valued at approximately $292 million, based on purchase price in the aggregate.
About Grubb & Ellis Healthcare REIT II
Grubb & Ellis Healthcare REIT II, Inc. intends to qualify as a real estate investment trust that seeks to preserve, protect and return investors' capital contributions, pay regular cash distributions, and realize growth in the value of its investments upon the ultimate sale of such investments. Grubb & Ellis Healthcare REIT II is seeking to raise up to approximately $3 billion in equity and to acquire a diversified portfolio of real estate assets, focusing primarily on medical office buildings and other healthcare-related facilities.
Grubb & Ellis Healthcare REIT II is sponsored by Grubb & Ellis Company (NYSE: GBE), one of the largest and most respected commercial real estate services and investment companies in the world. Our 5,200 professionals in more than 100 company-owned and affiliate offices draw from a unique platform of real estate services, practice groups and investment products to deliver comprehensive, integrated solutions to real estate owners, tenants and investors. The firm's transaction, management, consulting and investment services are supported by highly regarded proprietary market research and extensive local expertise. Through its investment management business, the company is a leading sponsor of real estate investment programs. For more information, visit www.grubb-ellis.com.
This release contains certain forward-looking statements (under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) with respect to the Dixie-Lobo Medical Office Building Portfolio's occupancy, whether the proximity of the buildings that comprise the portfolio to local hospitals is beneficial, and whether our property acquisitions are and will continue to be accretive to our bottom line and supportive of our investor distributions. Because such statements include risks, uncertainties and contingencies, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties and contingencies include, but are not limited to, the following: the uncertainties relating to the financial strength and financial condition of the properties that comprise the Dixie-Lobo Medical Office Building Portfolio and their tenants; uncertainties relating to the local economies of the properties that comprise the Dixie-Lobo Medical Office Building Portfolio; uncertainties relating to changes in general economic and real estate conditions; uncertainties regarding changes in the healthcare industry; the uncertainties relating to the implementation of our real estate investment strategy; and other risk factors as outlined in the company's prospectus, as amended from time to time, and as detailed from time to time in our periodic reports, as filed with the U.S. Securities and Exchange Commission. Forward-looking statements in this document speak only as of the date on which such statements were made, and we undertake no obligation to update any such statements that may become untrue because of subsequent events. We claim the safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
THIS IS NEITHER AN OFFER TO SELL NOR AN OFFER TO BUY ANY SECURITIES DESCRIBED HEREIN. OFFERINGS ARE MADE ONLY BY MEANS OF A PROSPECTUS OR OFFERING MEMORANDUM.
SOURCE Grubb & Ellis Healthcare REIT II, Inc
AVI BioPharma to Present Company Overview at the ThinkEquity 2nd Annual Healthcare Conference
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Thursday 19 May 2011
AVI BioPharma (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the company is scheduled to present at the ThinkEquity 2nd Annual Healthcare Conference in New York City on Wednesday, May 25, at 9 a.m. Eastern Time. Chris Garabedian, AVI's president and CEO, will provide a company overview.
The presentation will be Webcast live under the events section of AVI's website at www.avibio.com and will be archived there following the presentation for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
ACADIA Pharmaceuticals Awarded Grant from National Institutes of Health for the Development of Novel ER-beta Agonists
Acadia (NASDAQ:ACAD)
Intraday Stock Chart
Today : Tuesday 17 May 2011
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a grant from the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH), for the development of novel estrogen receptor beta (ER-beta) agonists for the treatment of neuropathic pain. The grant provides funding of up to $2.4 million and was awarded under the NINDS Fast-Track Small Business Innovative Research Cooperative Program in Translational Research that supports the identification and preclinical testing of new therapeutics for neurological disorders.
“We are delighted to be awarded this NINDS grant, which allows us to advance our promising ER-beta program in the area of neuropathic pain and provides important recognition of our scientific discoveries,” said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. “Our ER-beta compounds also offer the potential for an innovative disease-modifying approach to the treatment of Parkinson’s disease, and our initial studies in this area have been supported by grants from The Michael J. Fox Foundation.”
Studies have shown that estrogen modulates many cerebral functions such as mental state, mood, cognition and perception of pain. Estrogen stimulates both ER-alpha and ER-beta receptors. ACADIA researchers have identified novel and selective ER-beta agonists that may address the symptoms of chronic, inflammatory and neuropathic pain while avoiding the side effects associated with activating ER-alpha receptors. Pursuant to the grant, ACADIA will initially examine the efficacy of selected proprietary ER-beta compounds in preclinical models and intends to subsequently conduct preclinical development studies required in support of potential future clinical studies.
About Neuropathic Pain
Neuropathic pain is a debilitating disorder caused by damage or dysfunction of the nervous system and originates from many diverse sources including diabetic and hereditary neuropathies, herpes, chemotherapy, physical traumas and surgery. Current first-line medications are limited by variable efficacy and adverse effects. There is a major unmet medical need for novel, safe and effective drugs to treat neuropathic pain.
Today should be a big day foe AVI with todays news
AVI BioPharma Issued Broad Composition of Matter Patent for PMOplus(TM) Chemistry Platform
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Tuesday 17 May 2011
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the United States Patent and Trademark Office issued AVI a composition of matter patent for its advanced generation of phosphorodiamidate morpholino oligonucleotide (PMO) chemistry called PMOplus™. The patent, titled "Oligonucleotide Analogs Having Cationic Intersubunit Linkages" (No. 7943762), issued with broad composition of matter claims covering AVI's PMOplus chemistry. The PMOplus chemical backbone builds on AVI's exclusive charge-neutral PMO technology with the selective addition of positive charges to enhance potency and broaden the utility of AVI's PMO chemistry platform in a range of applications.
"The issuance of this patent is a key component to our ongoing efforts to advance a range of programs utilizing our PMOplus technology, including two recently initiated Phase 1 trials for our Ebola and Marburg programs that have garnered almost $300 million in potential funding support from the U.S. Department of Defense," said Chris Garabedian, AVI's CEO and president. "More broadly, the issuance of this patent represents another step in securing protection for the future development of our next generation morpholino chemistries, allowing us to confidently pursue new drug candidates for both internal development and development with potential collaborators and partners."
AVI recently initiated Phase 1 clinical investigations of two infectious disease drug candidates based on the PMOplus™ chemistry, AVI-6002 and AVI-6003, for Ebola and Marburg viruses, respectively. AVI plans to advance a third drug candidate also based on the PMOplus™ chemistry, AVI-7100, into the clinic this quarter for the H1N1 influenza virus. AVI-6002 and AVI-6003 have demonstrated up to 80% and 100% survival rates in preclinical studies treating non-human primates infected with the Ebola and Marburg viruses, respectively. AVI-7100 has demonstrated antiviral properties in preclinical studies of the H1N1 influenza virus. These programs have received support from the U.S. Department of Defense.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging a highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen (previously known as AVI-4658), which is in clinical development for the treatment of Duchenne muscular dystrophy.
Forward-Looking Statements and Information
This press release contains statements that are forward-looking, including statements about the development of AVI's product candidates; the efficacy, potency and utility of AVI's product candidates in the treatment of rare and infectious diseases; the potential for AVI's technology to treat a broad number of human diseases; AVI's expectations regarding future funding from the U.S. government; the extent of protection that AVI's patents provide to its technologies and programs; AVI's expectations regarding partnering opportunities; and AVI's plans to initiate a Phase 1 clinical trial in AVI-7100 in the second quarter of 2011. These forward-looking statements involve risks and uncertainties, many of which are beyond AVI's control. Known risk factors include, among others: clinical trials may not demonstrate safety and efficacy of any of AVI's drug candidates and/or AVI's antisense-based technology platform; any of AVI's drug candidates may fail in development, may not receive required regulatory approvals, or be delayed to a point where they do not become commercially viable; development of any of AVI's drug candidates may not result in funding from the U.S. government in the anticipated amounts or on a timely basis, if at all; and patents that have been issued may not afford meaningful protection for AVI's technology and products. Any of the foregoing risks could materially and adversely affect AVI's business, results of operations and the trading price of AVI's common stock. For a detailed description of risks and uncertainties AVI faces, you are encouraged to review the official corporate documents filed with the Securities and Exchange Commission. AVI does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
AVI Media and Investor Contact:
David A. Walsey
Senior Director, Investor Relations & Corporate Communications
425.354.5140
thanks for sharing maka
good thinkin
Quiet here, No one posting and i believe no shares traded all week, all i can say is WOW
ACADIA Pharmaceuticals Reports First Quarter 2011 Financial Results
Acadia (NASDAQ:ACAD)
Intraday Stock Chart
Today : Wednesday 11 May 2011
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2011.
ACADIA reported a net loss of $5.8 million, or $0.12 per common share, for the first quarter of 2011 compared to a net loss of $5.5 million, or $0.14 per common share, for the first quarter of 2010.
At March 31, 2011, ACADIA’s cash, cash equivalents and investment securities totaled $45.7 million compared to $37.1 million at December 31, 2010. ACADIA continues to expect that its existing cash resources and anticipated payments from its collaborations will be sufficient to fund its operations at least into the first half of 2013.
“The first quarter of 2011 was a productive period for ACADIA highlighted by solid progress in the execution of our lead Phase III program with pimavanserin for Parkinson’s disease psychosis, the successful completion of our private equity financing, and the extension of our longstanding discovery collaboration with Allergan,” said Uli Hacksell, Ph.D., ACADIA’s Chief Executive Officer. “ACADIA is positioned to advance and build substantial value in our pipeline of product candidates, led by our Phase III pimavanserin program.”
Revenues totaled $435,000 for the first quarter of 2011, compared to $2.1 million for the first quarter of 2010. This decrease was primarily due to the conclusion of ACADIA’s collaboration with Biovail in October 2010, at which time ACADIA recognized all remaining revenues related to this collaboration. ACADIA recognized $1.4 million in revenues from this collaboration in the first quarter of 2010.
Research and development expenses decreased to $4.4 million for the first quarter of 2011, including $120,000 in stock-based compensation, from $5.8 million for the first quarter of 2010, including $229,000 in stock-based compensation. This decrease was primarily due to $1.2 million in lower external service costs as well as reduced internal costs.
General and administrative expenses totaled $1.9 million for the first quarter of 2011, including $255,000 in stock-based compensation, and were comparable to the first quarter of 2010.
Conference Call and Webcast Information
ACADIA management will review its first quarter financial results and development programs via conference call and webcast later today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 866-825-3209 for participants in the U.S. or Canada and 617-213-8061 for international callers (reference passcode 78237908). A telephone replay of the conference call may be accessed through May 24, 2011 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 20761365). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com, under the investors section and will be archived there until May 24, 2011.
congrats bama
up .15 broke support, blueskies ahead